| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy—A single-institution experience
|
Yang, Guo-liang
|
|
2017
|
35 |
2 |
p. 38.e9-38.e15
3.7999962E16 p.
|
artikel
|
| 2 |
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer
|
Donin, Nicholas M.
|
|
2017
|
35 |
2 |
p. 39.e1-39.e7
3.89999611E8 p.
|
artikel
|
| 3 |
Clinically localized prostate cancer in 2017: A review of comparative effectiveness
|
Lavery, Hugh J.
|
|
2017
|
35 |
2 |
p. 40-41
2 p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
2017
|
35 |
2 |
p. i-
1 p.
|
artikel
|
| 5 |
From QOL to QALYs: Comparing nononcologic outcomes in prostate cancer survivors across treatments
|
Shirk, Joseph D.
|
|
2017
|
35 |
2 |
p. 69-75
7 p.
|
artikel
|
| 6 |
How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer
|
Lamers, Romy E.D.
|
|
2017
|
35 |
2 |
p. 37.e9-37.e17
3.699999963E18 p.
|
artikel
|
| 7 |
Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy
|
Chappidi, Meera R.
|
|
2017
|
35 |
2 |
p. 38.e17-38.e24
3.79999962E25 p.
|
artikel
|
| 8 |
Masthead
|
|
|
2017
|
35 |
2 |
p. IFC-
1 p.
|
artikel
|
| 9 |
Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies
|
Muralidhar, Vinayak
|
|
2017
|
35 |
2 |
p. 76-85
10 p.
|
artikel
|
| 10 |
Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan
|
Abe, Takashige
|
|
2017
|
35 |
2 |
p. 38.e1-38.e8
3.799999621E9 p.
|
artikel
|
| 11 |
Predictive models and risk of biopsy progression in active surveillance patients
|
Iremashvili, Viacheslav
|
|
2017
|
35 |
2 |
p. 37.e1-37.e8
3.699999631E9 p.
|
artikel
|
| 12 |
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model 1 1 Dr. Mizuno reports grants from The Japan Agency for Medical Research and Development (AMED), personal fees from Pfizer, grants and personal fees from Novartis, during the conduct of the study. Dr. Mikami reports grants from The Japan Agency for Medical Research and Development (AMED) during the conduct of the study. Dr. Oya reports grants from The Japan Agency for Medical Research and Development (AMED), grants and personal fees from Pfizer, grants and personal fees from Novartis, personal fees from Bayer, during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.
|
Tanaka, Nobuyuki
|
|
2017
|
35 |
2 |
p. 39.e19-39.e28
3.8999999961E29 p.
|
artikel
|
| 13 |
Prospective assessment and histological analysis of adherent perinephric fat in partial nephrectomies
|
Dariane, Charles
|
|
2017
|
35 |
2 |
p. 39.e9-39.e17
3.899999961E18 p.
|
artikel
|
| 14 |
Table of Contents
|
|
|
2017
|
35 |
2 |
p. ii-iii
nvt p.
|
artikel
|
| 15 |
The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer
|
Tyson, Mark D.
|
|
2017
|
35 |
2 |
p. 51-58
8 p.
|
artikel
|
| 16 |
The effect of an online support group on patients׳ treatment decisions for localized prostate cancer: An online survey
|
Huber, Johannes
|
|
2017
|
35 |
2 |
p. 37.e19-37.e28
3.6999999963E29 p.
|
artikel
|
| 17 |
What is the best way not to treat prostate cancer?
|
Leapman, Michael S.
|
|
2017
|
35 |
2 |
p. 42-50
9 p.
|
artikel
|
| 18 |
What is the best way to radiate the prostate in 2016?
|
Moon, Dominic H.
|
|
2017
|
35 |
2 |
p. 59-68
10 p.
|
artikel
|
Tijdschrift beschrijving